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Summary
Background Polypharmacy, defined as use of five or more medications concurrently, is associated with adverse health 
outcomes and people ageing with HIV might be at greater risk than similar uninfected individuals. We aimed to 
determine whether known pairwise drug interactions (KPDIs) were associated with risk of admission to hospital 
(hereafter referred to as hospitalisation) and medication count among people ageing with and without HIV after 
accounting for physiological frailty.
Methods In this observational study, we collected individual-level data for participants of the Veterans Aging Cohort 
Study (VACS) with HIV on antiretroviral therapy (ART) and with supressed HIV-1 RNA and people without HIV who 
were receiving at least one prescription medication, based on active medications in the 2009 fiscal year (ie, Oct 1, 2008, 
to Sept 30, 2009). We identified KPDIs among these patients by linking prescription fill and refill data with data from 
DrugBank (version 5.0.11). We collected data on all-cause mortality and hospitalisations between Oct 1, 2009, and 
March 31, 2019. We compared KPDI counts using random selection and actual patterns of use across medication 
counts from two to 12. We created a weighted KPDI Index on the basis of the average association of each KPDI with 
mortality among people ageing without HIV and used nested Cox models stratified by HIV status to estimate the 
association between medication count and hospitalisation, with incremental adjustments for demographics, 
physiological frailty, and KPDI Index.
Findings We collected data for 9186 people ageing with HIV and 37 930 individuals without HIV. 45 913 (97·4%) of 
47 116 patients were men and the sample was predominantly aged 50–64 years (30 413 [64·6%]). Compared with a 
random sample of medications, real-world pattern of medication counts and combinations were associated with five-
to-six times more KPDIs (eg, for a combination of six medications, KPDI count was 1·09 in the random sample, 
5·49 in the HIV-negative population, and 7·13 in the HIV-positive population). For each additional observed 
medication, people ageing with HIV had approximately 2·94 additional KPDIs and comparators had approximately 
2·67 additional KPDIs. Adjustment for demographics, physiological frailty, and KPDI Index reduced the association 
between medication count and risk of hospitalisation for people ageing with HIV (hazard ratio 1·08 [95% CI 
1·07–1·09] reduced to 1·06 [1·05–1·07]) and those without HIV (1·08 [1·07–1·08] reduced to 1·04 [1·03–1·05]).
Interpretation For each additional medication, people ageing with HIV have more drug–drug interactions than those 
without HIV. Adjusting for known non-ART drug–drug interactions, each additional non-ART medication confers 
excess risk of hospitalisation for people ageing with HIV. Randomised trials will be needed to determine whether 
reducing these interactions improves outcomes.
Funding National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Department of Veterans 
Affairs Health Services Research & Development, and Office of Research and Development.
Copyright Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Polypharmacy is the simultaneous use of multiple 
medications (often five or more)1 and is widespread among 
older adults in North America and Europe.2,3 Polypharmacy 
is associated with non-adherence,4 adverse drug events,5 
falls,6 opioid overdose,7 and adds substantial complexity to 
medical regimens, thereby contributing to inappropriate 
prescribing.8 It is also associated with admission to hospital 
(hereafter referred to as hospitalisation)9 and mortality1 in a 
dose-response manner.
Polypharmacy might be particularly problematic for 
people ageing with HIV. People ageing with HIV might be 
more susceptible to adverse effects from specific 
medications and to cumulative injury from polypharmacy 
than demographically similar uninfected individuals 
(figure 1).10 Although antiretroviral therapy (ART) is life 
preserving, it must be sustained for a patient’s lifetime 
and typically includes three active medications. People 
ageing with HIV typically have polypharmacy a decade 
earlier than uninfected individuals.11 Furthermore, 
compared with demo graphically similar uninfected 
individuals, people ageing with HIV have excess 
physiologial frailty,12 making them more susceptible to the 
adverse effects of medications. An increased number of 
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medications being taken concomitantly increases the 
probability of harmful interactions with other medications, 
alcohol, and other substances, and with individuals’ 
differing pharmaco genomics.7,13,14
ART medications commonly interact with non-ART 
medications.15 For example, boosted regimens, including 
protease inhibitors and the early integrase strand transfer 
inhibitor elvitegravir–cobicistat, can increase drug 
concentrations and risk of adverse effects of co-
medications via inhibition of CYP3A4 and transporters.16 
Interactions between ART and non-ART medications are 
associated with hospitalisation after adjusting for CD4 
cell count, protease inhibitor-based regimen, substance 
use, and non-ART medication count.17 While now being 
prescribed less frequently, use of boosted regimens 
remains common.18 To date, no study has considered the 
association between hospitalisation and all pairwise 
drug interactions including both ART–non-ART and 
non-ART–non-ART medication interactions among 
people ageing with HIV.
The greatest limitation for observational studies of 
polypharmacy is confounding by indication (individuals 
who are sicker or more frail are on more medications).19 
One approach to partially address this confounding is to 
adjust for physiological frailty. Based on routine clinical 
laboratory data, the Veterans Aging Cohort Study (VACS) 
Index (version 1.0) has been validated as a highly 
discriminating and generalisable measure of physiological 
frailty in people ageing with HIV and people ageing 
without HIV.12
We previously found in a large national study done in 
the USA that among people with and without HIV, that 
risk of hospitalisation and mortality increased with 
increasing medication count after adjustment for VACS 
Index 1.0 score.20 Our findings suggested that 
confounding by indication alone did not explain the 
association between polypharmacy and adverse health 
outcomes. Subsequently, we have developed and 
validated an even more discriminating measure of 
physiological frailty (VACS Index version 2.0).21 In the 
current study, we aimed to further enhance our 
adjustment for physiological frailty using VACS 
Index 2.0.
Finally, the potential list of drug interactions is large 
and highly complex, but known pairwise drug interactions 
(KPDIs) have been meticulously catalogued in a 
centralised database, DrugBank.22 DrugBank includes 
KPDI information for US Food and Drug Association-
approved drugs. DrugBank version 5.0.11 provides a 
catalogue of 365 984 evidence-based KPDIs. Linking these 
data to a clinical cohort and analysing associations 
required innovative methods. Although similar databases 
exist, DrugBank attempts to be as comprehensive as 
possible and was updated in 2018.
Research in context
Evidence before this study
We did a related article search in PubMed on July 23, 2021, using 
a review of polypharmacy and HIV (PMID 31833963). 
This search yielded 98 articles published in the period 2004–21, 
a pool that was then restricted to just articles on HIV or with HIV 
in the title or abstract, which left 34 articles. We reviewed the 
abstracts of these articles and found that 20 addressed 
polypharmacy among individuals with HIV. These articles 
reported data from North America, Europe, and Australia. 
Six articles considered the association of medication count with 
a clinical outcome (falls or fractures, discontinuation or non-
adherence to antiretroviral treatment, and non-fatal opioid 
overdose). Only our previous publication considered 
associations with admission to hospital (ie, hospitalisation) and 
mortality. Most studies found a substantial prevalence of 
polypharmacy, which increased with increased age. Several 
studies showed increasing prevalence of polypharmacy among 
people ageing with HIV over calendar time. Ten articles 
considered the association of medication count with potentially 
inappropriate medications. These studies showed that 
potentially inappropriate medications and  antiretroviral 
therapy (ART)–non-ART medication interactions increase with 
increasing medication count. Five previous studies compared 
polypharmacy frequency by HIV status, which found that, 
controlling for age, polypharmacy was more common among 
people with HIV infection.
Added value of this study
We used large scale, real-world data to consider how much of 
the association between polypharmacy and hospitalisation 
might be explained by known pairwise drug interactions not 
restricted to ART–non-ART interactions. We used an updated 
and validated measure of physiological frailty to account for 
confounding by indication. No previous study has considered 
the association between drug–drug interactions among 
people ageing with HIV and hospitalisation, compared this 
association with that observed for uninfected individuals, or 
considered how much of the association between 
polypharmacy and hospitalisation is explained by established 
drug–drug interactions.
Implications of all the available evidence
Polypharmacy is an increasing problem worldwide, with 
particularly important implications for those ageing with HIV. 
In future, we hope to apply our index of known pairwise drug 
interactions to more recent data (ie, from the past 5 years) to 
determine whether the differences between people ageing 
with and without HIV remain. Regardless, providers should 
obtain a complete list of medications, consider non-
pharmacological treatments where feasible, and select non-
ART medications to minimise polypharmacy and associated 
drug–drug interactions. Where possible, electronic decision 
support might greatly facilitate these efforts.
For DrugBank website see 
https://go.drugbank.com/
Articles
www.thelancet.com/healthy-longevity   Vol 22   October 2021 e641
To better understand mechanisms underlying harms 
due to polypharmacy among people ageing with and 
without HIV infection, we added DrugBank data, created 
a KPDI Index, extended follow-up, and updated our 
physiological frailty index (VACS Index 2.0) to extend our 
previous study.20 Here, we explored the association 
between KPDI and medication count, considering both 
ART and non-ART medications; determined the degree 
to which KPDIs drive the association between non-ART 
medication count and hospitalisation, test whether 
associations differ by HIV status; and determine how 
much risk of hospitalisation associated with non-ART 
medication count remains after better accounting for 
physiological frailty and KPDIs.
Methods 
Study design and population 
In this observational study, we included people ageing 
with HIV receiving ART who had suppressed HIV-1 RNA 
(ie, ≤400 copies per mL) and people without HIV who 
were receiving at least one prescription medication from 
the US Veterans Affairs Healthcare System (VA) in the 
fiscal year of 2009 (Oct 1, 2008, to Sept 30, 2009). Briefly, 
the VACS is a longitudinal, multicentre, observational 
study of HIV infected and uninfected individuals who 
receive care in the national VA health-care system in the 
USA. Enrolment began in 1999 and additional patients 
are added and followed up each year. 
For this analysis, patients were followed up from 
Oct 1, 2009, until March 31, 2019, for hospitalisation and 
all-cause mortality. Cohort characteristics, measurement 
of medication exposure, and outcomes are the same as in 
the original publication.20 More details of our methods 
are provided in the  appendix (pp 1–4).20
As in the original study,20 we restricted our analysis to 
medications filled on a chronic basis, defined as at least 
90 consecutive days allowing for a 30 day refill window, 
consistent with previous definitions.23 These data were 
extrapolated from pharmacy data from the VA. We 
calculated days of receiving medication on the basis of 
medication fill refill information, assuming the 
medication was taken as directed. Patients might have 
started a medication before the 2009 fiscal year or 
continued them after the fiscal year; we only captured 
days supplied within this fiscal year. We counted each 
component of co-formulated medications separately. In 
this analysis, we included longer-term follow-up and use 
VACS Index 2.0 rather than VACS Index 1.0 for 
physiological frailty adjustment.
VACS Index 
We used the VACS Index 2.0 to adjust for frailty.12,21 The 
VACS Index 1.0 and 2.0 are indices of physiological frailty 
that can be used to predict the risk of all-cause mortality 
and were initially developed using a cohort of people 
ageing with HIV. VACS Index 1.0 integrates data on age, 
HIV biomarkers (HIV-1 RNA viral load, CD4 cell count), 
and non-HIV biomarkers (haemoglobin, hepatitis C, 
Fibrosis-4 [known as FIB-4] score  to assess liver function, 
and estimated glomerular filtration rate to assess renal 
function). VACS Index 2.0 improves on the discrimination 
observed using VACS Index 1.0 by adding body-mass 
index, albumin, white blood cell count, and continuous 
functional forms for all variables. Neither index includes 
HIV status, thereby enabling application to uninfected 
individuals. Both indices include viral load level (assumed 
0 in HIV-negative individuals) and CD4 cell count 
(assumed to be greater than 500 cells per mm³ in HIV-
negative individuals). The VACS Index has been validated 
in HIV-negative individuals.12 Scores typically range from 
0 to 100, with higher scores indicating a greater risk of 
mortality from physiological injury. A five-point increase 
in VACS Index 2.0 score is associated with a 30% increase 
in 5 year mortality risk.21 We determined scores using 
Figure 1: Mechanisms of harm from polypharmacy for people ageing with HIV compared with those without HIV
Medication interactions with: Co-occurring exposures 
Substance use (higher among 




Substance use Antiretroviral 
medication
Provider distraction and 
prescription of potentially 
inappropriate medications





Polypharmacy (occurs an average 
of 10 years earlier among 
HIV-positive populations than 
among HIV-negative populations) 
Physiological frailty (occurs with 
greater frequency in HIV-positive 




See Online for appendix
Articles
e642 www.thelancet.com/healthy-longevity   Vol 22   October 2021
laboratory values closest to the end of the 2009 fiscal year. 
The requirement of the additional variables for the VACS 
Index 2.0 versus 1.0 slightly reduced our sample size from 
that in our original analyses (from 9473 patients ageing 
with HIV in the original analysis to 9186 and people 
ageing without HIV from 39 812 to 37 960).20
DrugBank mapping, Drug Interaction Network, and co-
occurrence matrix 
We parsed the DrugBank (version 5.0.11) database22 for 
drug interactions between medications taken by the 
cohort. We initially mapped drugs to synonyms and 
base terms in the DrugBank database. Any drugs that 
did not have an automatic mapping to DrugBank were 
manually assessed to determine if there was a matching 
DrugBank term. All drugs without a matching term in 
DrugBank were excluded. Drugs dispensed from the 
pharmacy were further split into subsets by removing 
herbal and dietary supplements (eg, fish oil, vitamins 
and minerals, peppermint oil), vaccines, water, non-
specific skin ointments and lubricants, and other non-
specific terms. Matching, subsetting, and exclusion 
resulted in a reduction of 159 drugs (from 709 to 550).
We then created a Drug Interaction Network from the 
drugs within the database (nodes) and KPDIs (edges). The 
resulting network was visualised with Cytoscape (version 
3.80).24 We created a calendar for each patient, mapping 
start and stop times for each drug to their respective dates. 
All days in between the start and stop date were counted 
as the days a patient was on a given medication. Two or 
more medications were said to have an overlap if a given 
patient was taking both or each drug on at least 1 day in 
common. We removed duplicates of medication overlaps 
to give us a set of unique co-medications for each patient. 
We then created a matrix (called the Drug Co-Occurrence 
Matrix) using all the co-medications for all patients.
Simulated drug set interactions 
We first considered KPDIs that might occur in theory, by 
chance alone. We did this by writing a Perl program to 
generate random drug sets for a population size of 
44 350 individuals. This number of individuals is less than 
the entire sample because an individual must be on at 
least two medications to have a drug–drug interaction. 
Specifically, 44 350 drug sets were generated randomly for 
each set of medications from two to 12 (including ART 
medications). Each set was used in conjunction with the 
Drug Interaction Network to determine how many known 
drug interactions were contained within each set. Briefly, 
all possible pairs of drugs within the DrugBank database 
were generated and the Drug Interaction Network queried 
for the presence of an interaction edge between each pair 
of drugs. The minimum, maximum, and mean number 
and SD of drug interactions were calculated across all sets 
for each set size. To test the effect of population size on 
this simulation, we did a similar random drug interaction 
simulation on a population size of 20 000 000 individuals 
and found that the results were not sensitive to this 
difference in population size. Results are shown from the 
smaller sample in the Results section.
Then, we wrote another Perl program to generate drug 
sets from the Drug Co-Occurrence Matrix. These sets 
were then used in conjunction with the Drug Interaction 
Network to determine how many KPDIs  were contained 
within each set. Briefly, all observed pairs of drugs for 
each patient were generated and the Drug Interaction 
Network queried for the presence of an interaction edge 
between each pair of drugs. The minimum, maximum, 
 Overall (n=47 116) People ageing with  
HIV (n=9186)
People ageing without 
HIV (n=37 930)
Age, years
<50 10 004 (21·2%) 2249 (24·5%) 7755 (20·5%)
50–64 30 413 (64·6%) 5683 (61·9%) 24 730 (65·2%)
≥65 6699 (14·2%) 1254 (13·7%) 5445 (14·4%)
Sex
Female 1203 (2·6%) 196 (2·1%) 1007 (2·7%)
Male 45 913 (97·4%) 8990 (97·9%) 36 923 (97·4%)
Race
White, non-Hispanic 19 309 (41·0%) 4012 (43·7%) 15 297 (40·3%)
Black, non-Hispanic 21 934 (46·6%) 4044 (44·0%) 17 890 (47·2%)
Hispanic 4167 (8·8%) 779 (8·5%) 3388 (8·9%)




20 567 (43·7%) 3496 (38·1%) 17 071 (45·0%)
Hypertension, 
uncontrolled
10 081 (21·4%) 1593 (17·3%) 8488 (22·4%)
Diabetes 15 304 (32·5%) 1996 (21·7%) 13 308 (35·1%)
Hyperlipidaemia 19 767 (42·0%) 3590 (39·1%) 16 177 (42·7%)
Coronary artery disease 4621 (9·8%) 669 (7·3%) 3952 (10·4%)
Chronic obstructive 
pulmonary disease
3233 (6·9%) 494 (5·4%) 2739 (7·2%)
Cirrhosis 551 (1·2%) 163 (1·8%) 388 (1·0%)
Chronic pain 22 826 (48·5%) 3332 (36·3%) 19 494 (51·4%)
Gastro-oesophageal reflux 
disease
5126 (10·9%) 631 (6·9%) 4495 (11·9%)
Obesity (BMI ≥35 kg/m2) 7850 (16·7%) 444 (4·8%) 7406 (19·5%)
Psychiatric diagnoses
Major depression 3592 (7·6%) 771 (8·4%) 2821 (7·4%)
Bipolar disorder 2824 (6·0%) 483 (5·3%) 2341 (6·2%)
Post-traumatic stress 
disorder
6529 (13·9%) 735 (8·0%) 5794 (15·3%)
Schizophrenia 2640 (5·6%) 211 (2·3%) 2429 (6·4%)
Any psychiatric disorder 13 004 (27·6%) 1858 (20·2%) 11 146 (29·4%)
Substance use
Alcohol-related diagnosis 5048 (10·7%) 793 (8·6%) 4255 (11·2%)
Drug abuse and 
dependence
4692 (10·0%) 1072 (11·7%) 3620 (9·5%)
Alcohol or drug diagnoses 7105 (15·1%) 1360 (14·8%) 5745 (15·2%)
Current smoker 23 527 (49·9%) 4827 (52·6%) 18 700 (49·3%)
Former smoker 8622 (18·3%) 1519 (16·5%) 7103 (18·7%)
(Table 1 continues on next page) 
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and mean number and SD of drug interactions were 
calculated across the sets for each set size from two to 12 
(including ART medications).
KPDI Index 
We sought to develop a summary weighted measure of 
KPDIs on the basis of the average association of each 
KPDI with mortality among individuals who were HIV 
negative. Using mortality as the outcome event and 
focusing on HIV-negative individuals, we trained a Cox 
proportional hazards model to create a beta coefficient for 
each KPDI. We focused on HIV-negative individuals to 
weight the interactions in the largest subset, without the 
effects of HIV infection and antiretrovirals. We did this 
with a program, written in Python, using the Drug 
Co-occurrence Matrix. Drug interactions with fewer than 
ten instances were removed due to low prevalence in the 
population.
To mitigate overfitting, we used a technique called 
bagging that is commonly used in machine learning, in 
which the same calculation is done on different subsets 
of the data (ie, different bags) hundreds of times. The 
resulting average of the different bags is more robust to 
sample bias and produces more accurate predictors.25 
The dataset was sampled with replacement for 
1000 iterations producing subsets that contained the 
same number of total samples and for each iteration a 
model was built for each KPDI. Subsets with hazard ratio 
(HR)-associated p values of more than 0·05 were 
assigned an HR of 1·0. And the results of each KPDI 
with an HR with a p value of less than 0·05 were averaged 
across the iterations for each KPDI and a 95% CI for the 
HR was calculated for each.
We then used these estimates to create a KPDI Index, 
weighted by the period of exposure to each KPDI within 
the year of observation. We did this by summing the beta 
coefficients associated with each KPDI across all KPDIs 
to which the patient was exposed to generate a KPDI 
Index for each patient on the log hazard scale. We 
analysed this index as both a continuous measure and 
separated into ranked quintiles with approximately 
equal numbers of death (among the uninfected 
comparators) occurring in each quintile. Fully adjusted 
models estimating HRs for medication count in which 
the KPDI is treated as an indicator variable rather than 
as a continuous measure had a superior model fit. Here, 
we show only the indicator models. The range of values 
for the KPDI Index estimated on those without HIV was 
from –5·6 to 30·7. Negative values correspond to a 
protective association with mortality, whereas higher 
positive values correspond to a greater risk of mortality.
Notably, the KPDI Index score for an individual drug 
pair from DrugBank measures the association the drug 
pair has to mortality, controlling for overall health, by 
incorporating the VACS Index 2.0 in the model. By 
bootstrapping across multiple subsampled sets, we 
ensured that only the most robust associations were 
considered to be significant. We used this method to 
ensure that both potentially spurious correlations and 
drug pairs with low effect have low-to-zero weight in the 
final model.
Additional statistical analyses
We did a descriptive analysis of the study sample overall 
and by HIV status. We did an analysis of bivariate 
associations by randomly selecting among all medications 
included medication counts and comparing their 
association with KPDI to actual medication counts by HIV 
status. Because people ageing without HIV infection do 
not take ART, we only considered non-ART medications 
when considering medication count and when developing 
the KPDI Index. However, because ART medications 
interact with many non-ART medications, we considered 
both when calculating counts of drug–drug interactions. 
We used Pearson’s correlation to determine the association 
 Overall (n=47 116) People ageing with  
HIV (n=9186)
People ageing without 
HIV (n=37 930)
(Continued from previous page)
VACS Index score and components 
Total score 34 (27–43) 48 (39–58) 32 (26–39)
Age, years 56 (51–62) 56 (50–61) 56 (51–62)
HIV-1 RNA, copies per mL NA <400 NA
CD4 count, cells per mm3 NA 511 (346–720) NA
Haemoglobin, dL 14 (13–15) 14 (13–15) 14 (14–15)
Fibrosis-4 score 1·19 (0·89–1·66) 1·38 (1·00–1·97) 1·15 (0·87–1·59)
Estimated glomerular 
filtration rate, mL/min per 
1·73 m2
88 (73–102) 88 (73–104) 88 (73–102)
White blood cell count, 
×109 per L
7 (5–8) 6 (5–7) 7 (6–8)
Albumin, g/dL 4·1 (3·9–4·4) 4·1 (3·8–4·5) 4·1 (3·9–4·4)
BMI, kg/m2 29 (25–33) 26 (23–29) 30 (26–34)
Hepatitis C infection 9085 (19·3%) 3163 (34·4%) 5922 (15·6%)
Medication classes
ACE inhibitors 15 625 (33·2%) 2389 (26·0%) 13 236 (34·9%)
β blockers 13 301 (28·2%) 1989 (21·7%) 11 312 (29·8%)
Diuretics 9718 (20·6%) 1388 (15·1%) 8330 (22·0%)
Calcium-channel blockers 10 990 (23·3%) 1297 (14·1%) 9693 (25·6%)
Lipid-lowering agents 23 861 (50·6%) 3855 (42·0%) 20 006 (52·7%)
Oral glucose-lowering 
agents
9326 (19·8%) 980 (10·7%) 8346 (22·0%)
Gastric medications 14 184 (30·1%) 1766 (19·2%) 12 418 (32·7%)
Antidepressants 14 664 (31·1%) 2937 (32·0%) 11 727 (30·9%)
Non-opioid analgesics 12 222 (25·9%) 1722 (18·8%) 10 500 (27·7%)
Genitourinary agents 9435 (20·0%) 1797 (19·6%) 7638 (20·1%)
Outcomes
Hospitalisaton 25 846 (54·9%) 5609 (61·1%) 20 237 (53·4%)
All-cause death 10 881 (23·1%) 2329 (25·4%) 8552 (22·6%)
Data are n (%) or median (IQR). ACE=angiotensin-converting enzyme. BMI=body-mass index. NA=not applicable. 
VACS=Veterans Aging Cohort Study.
Table 1: Baseline characteristics of sample overall and by HIV status
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between medication count and VACS and KPDI Index 
score. We calculated unadjusted mortality and 
hospitalisation rates per 1000 person-years by dividing the 
number of observed events by the person-years of 
observation. We used nested Cox models stratified by HIV 
status to estimate the association between medication 
count and hospitalisation—incrementally adjusting for 
age per 10 years, sex, race, VACS Index score per 5 point 
increase , and KPDI Index score by quintile and risk of 
hospitalisation. In these analyses, we censored patients on 
date of death or, if alive at the end of follow-up, on 
March 31, 2019. In our nested model we adjusted for 
demographics, physiological frailty, and KPDI index to 
understand the relative explanatory power of each of 
these components for the overall association between 
medication count and hospitalisation. We assessed the 
proportional hazards assumption by including 
interactions of exposure variables with follow-up time. 
The interactions with medication count and with sex were 
not significant for those with and without HIV. 
All p values of less than 0·05 were considered to be 
significant. We did all additional statistical analyses using 
SAS (version 9.4).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
During the 2009 fiscal year (baseline), 9186 people ageing 
with HIV in the VACS were on ART with suppressed 
HIV-1 RNA and 37 960 people ageing without HIV 
received at least one medication from the VA pharmacy 
(table 1). The cohort was predominantly aged 50–64 years 
(30 413 [64·6%] of 47 116), racially and ethnically diverse, 
male (45 913 [97·4%]), and demographically similar by 
HIV status. Both people ageing with HIV and people 
ageing without HIV were engaged in care, with the mean 
number of health-care visits per year among people 
ageing with HIV being 2·1 (SD 1·1) and in people ageing 
without HIV being 1·9 (1·0). Among people ageing with 
HIV, median CD4 count was 511 cells per mm³ 
(IQR 346–720). Consistent with our inclusion criteria, all 
people ageing with HIV were on ART (5613 [61·1%] of 
9186 were on protease inhibitors, 3618 [39·4%] were on 
non-nucleoside reverse transcriptase inhibitors, and 
five [<0·1%] were on an integrase inhibitors) and had 
HIV-1 RNA concentrations of 400 copies per mL or lower. 
Overall, non-ART medication counts were lower for 
people ageing with HIV than those without HIV (mean 
count: 3 [SD 3] vs 4 [3]). People ageing with HIV had 
higher VACS Index 2.0 scores, suggesting greater 
physiological frailty than those without HIV (mean score: 
50 [SD 15] vs 33 [11]). Hospitalisation rates were higher for 
people ageing with HIV (108·9 admissions [95% CI 
106·1–111·8] per 1000 person-years) than those without 
HIV (87·5 admissions [86·3–88·7] per 1000 person-
years). Mortality rates were also higher among people 
ageing with HIV (30·6 [95% CI 29·4–31·9] per 
1000 person-years) than among those without HIV 
(26·6 [95% CI 26·0–27·2] per 1000 person-years).
When ART and non-ART medications were randomly 
selected, the association between medication count and 
KPDI count was linear (y = 0·51 x – 1·73; R² = 0·97; 
figure 2). For each additional medication, random 
selection predicted an additional 0·51 KPDIs. When 
actual medications were considered by HIV status, the 
slope of the association was steeper but remained linear. 
For each additional medication, people ageing without 
Figure 2: Theoretical and observed associations of medication count (including both ART and non-ART 
medications) and KPDIs
Datapoints are estimates for each dataset at each medication count, with dotted lines joining these datapoints to 
show the linear association. ART=antiretroviral therapy. KPDI=known pairwise drug interaction.
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HIV had an additional 2·67 KPDIs (y = 2·67 x – 9·38; 
R² = 0·97) and people ageing with HIV had an additional 
2·94 KPDIs (y = 2·94 x – 9·45; R² = 0·98; figure 2). 
Medication count was weakly correlated with VACS 
Index 2.0 score (Pearson correlation 0·11 for both groups; 
data not otherwise shown).
People ageing with and without HIV with no KPDIs 
had low non-ART medication counts and higher all-
cause mortality rates than those in the lowest KPDI 
Index quintile, even though their VACS Index scores 
were similar (table 2). People ageing with HIV and 
without HIV in the lowest KPDI Index quintile were 
taking two to three more medications than those with no 
KPDIs; however, they had lower mortality rates 
(22 vs 27 deaths per 1000 person-years for people ageing 
with HIV and 15 vs 17 deaths per 1000 person-years for 
people ageing without HIV) and similar VACS Index 
scores than those having no KPDIs. Although, KPDI 
Index score correlated with medication count overall 
(Pearson correlation 0·46; data not otherwise shown), we 
observed J-shaped associations between quintiles of 
KPDI Index score and non-ART medication count for 
both those ageing with and without HIV (table 2). People 
ageing with and without HIV in the second KPDI Index 
score quintile were taking the fewest non-ART 
medications of any quintile. This observation was also 
true for crude mortality rates, which were similar 
between KPDI Index quintile 1 and 2 for people ageing 
with HIV but were higher in quintile 2 than in quintile 1 
for people ageing without HIV (table 2). However, VACS 
Index 2.0 scores were similar across quintiles 1 and 2 for 
both groups. Those in the KPDI Index quintiles 3, 4, and 
5 were taking progressively more non-ART medications, 
had increasing VACS Index 2.0 scores, and had 
increasing rates of mortality regardless of HIV status 
(table 2).
In a series of nested models, we explored the association 
between non-ART medication count and risk of 
hospitalisation, stratified by HIV status (table 3). In 
unadjusted analyses, non-ART medication count was 
similarly associated with risk of hospitalisation among 
people ageing with HIV (HR 1·08 [95% CI 1·07–1·09]) 
and among those without HIV (1·08 [1·07–1·08]). 
Adjusting for demographics and physiological frailty 
(determined by VACS Index 2.0 score) resulted in a slight 
decrease in the association, similarly in people ageing 
with HIV (HR 1·07 [1·06–1·08]) and in those without 
HIV (1·07 [1·06–1·07]). Further adjusting for KPDI Index 
reduced the risk of hospitalisation associated with 
medication count for both people ageing with HIV (1·06 
[1·05–1·07] and those without HIV (1·04 [1·03–1·05]).
Discussion 
Our study offers several new insights into the complex 
problem of polypharmacy and its implications for people 
ageing with and without HIV infection. First, across a 
range of commonly observed non-ART medication 
counts, KPDIs are five-to-six times more common in 
real-world data than if medications are randomly 
selected. This higher number of interactions is probably 
because medications that are given to address specific 
health conditions have overlapping mechanisms and 
adverse events. This was particularly true for people 
ageing with HIV, most likely because ART medications 
have an exceptionally large number of drug–drug 
interactions.16,26 Second, after adjustment for 
demographics and physiological frailty, the KPDI Index 
based on non-ART medications explained an important 
portion, but by no means all, of the remaining association 
between polypharmacy and risk of hospitalisation. After 
full adjustment, the remaining associations were 
stronger for people ageing with HIV than those without 
HIV. This finding was also true when the KPDI Index 
included ART medications. These results suggest that 
KPDIs are major contributors to morbidity for people 
ageing with and without HIV and that both groups are 
susceptible to harms due to polypharmacy that are not 
reflected in KPDIs alone. They also suggest that people 
ageing with HIV might be more susceptible to harm 
from polypharmacy than those without HIV, both due to 
KPDIs and other mechanisms of injury. Third, our 
results suggest that beneficial effects of individual 
medications might be diminished and possibly lost as 
the total count increases.
We previously showed that non-ART medication count 
has a strong dose–response association with mortality 
and hospitalisation among people ageing with HIV and 
demographically similar uninfected individuals.20 An 
independent association remained before and after 
adjustment for general physiological frailty using VACS 
Index 1.0.20 However, that analysis could not differentiate 






All-cause deaths per 
1000 person-years 
(95% CI)
People ageing with HIV
No KPDIs 473 0 (0) 1·09 (0·82) 49 (15) 27 (22 to 32)
KPDI Index quintile 1 1161 –0·43 (0·43) 4·57 (2·38) 48 (14) 22 (20 to 26)
KPDI Index quintile 2 3688 0·00 (0·03) 2·15 (1·58) 47 (14) 21 (20 to 23)
KPDI Index quintile 3 2010 0·34 (0·19) 4·34 (2·22) 52 (15) 37 (34 to 40)
KPDI Index quintile 4 1263 1·45 (0·54) 6·56 (2·55) 54 (15) 47 (43 to 51)
KPDI Index quintile 5 591 5·02 (2·34) 9·01 (2·87) 57 (16) 63 (56 to 71)
People ageing without HIV
No KPDI 7793 0 (0) 1·20 (0·90) 31 (11) 17 (16 to 18)
KPDI Index quintile 1 5832 –0·44 (0·45) 4·54 (2·40) 32 (10) 15 (14 to 16)
KPDI Index quintile 2 6816 0·01 (0·05) 2·91 (1·83) 32 (10) 19 (18 to 20)
KPDI Index quintile 3 8503 0·35 (0·19) 4·45 (2·20) 34 (10) 27 (26 to 28)
KPDI Index quintile 4 5816 1·47 (0·54) 6·69 (2·50) 36 (11) 41 (39 to 43)
KPDI Index quintile 5 3170 5·46 (3·18) 9·36 (2·62) 39 (12) 76 (72 to 79)
Data are n, mean (SD), or mean (95% CI). ART=antiretroviral therapy. KPDI=known pairwise drug interaction. VACS= 
Veterans Aging Cohort Study.
Table 2: Association between KPDI Index score, non-ART medication count, VACS Index 2.0 score, and all-
cause mortality rates in people ageing with and without HIV
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between mechanisms of injury. In the current study, by 
applying data science techniques to DrugBank data in 
our real-world cohort, we were able to consider the role of 
KPDIs. We also applied VACS Index 2.012,21 to more 
completely account for confounding by indication.
ART extends survival but must be taken for the rest of 
a patient’s life. Furthermore, ART initiation typically 
precipitates polypharmacy a full decade earlier for people 
ageing with HIV than those without HIV.11 ART 
medications interact with a wide range of common 
medications including lipid-lowering agents, antihyper-
tensives, antidepressants, proton-pump inhibitors, and 
opioid agonists.15,16 However, no ready means of counting 
known drug–drug interactions, accounting for their 
differential effects, or comparing these by HIV status, 
has previously been available.
We were able to overcome these limitations using the 
DrugBank database combined with machine learning, 
simulation, and real-world data. Our simulation 
suggested, on average, an additional drug interaction for 
Unadjusted Progressively adjusted for additional factors
Adjusted for 
demographics
Adjusted for demographics 
and severity of illness
Adjusted for demographics, 
severity of illness, and KPDI Index
People ageing with HIV (n=9186)
Non-ART medication count 1·08 (1·07–1·09) 1·08 (1·07–1·09) 1·07 (1·06–1·08) 1·06 (1·05–1·07)
Age per 10 years ·· 1·13 (1·10–1·16) 0·96 (0·93–0·99) 0·96 (0·93–0·99)
Sex
Female  ·· 1·13 (0·94–1·34) 1·07 (0·89–1·27) 1·07 (0·90–1·28)
Male 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Race
White, non-Hispanic 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Black, non-Hispanic  ·· 1·27 (1·20–1·34) 1·16 (1·10–1·23) 1·17 (1·10–1·24)
Hispanic  ·· 1·16 (1·05–1·28) 1·11 (1·01–1·22) 1·11 (1·01–1·23)
Other  ·· 0·72 (0·61–0·85) 0·73 (0·62–0·86) 0·74 (0·63–0·87)
VACS Index 2.0 per 5 points  ··  ·· 1·11 (1·10–1·12) 1·11 (1·10–1·12)
KPDI Index score 
No KPDI  ··  ··  ·· 1·10 (0·97–1·25)
KPDI Index quintile 1  ·· ·· ·· 1·03 (0·94–1·13)
KPDI Index quintile 2  ·· ··  ·· 1 (ref)
KPDI Index quintile 3  ·· ·· ·· 1·12 (1·04–1·21)
KPDI Index quintile 4  ··  ··  ·· 1·14 (1·04–1·26)
KPDI Index quintile 5  ··  ·· ·· 1·12 (0·98–1·28)
People ageing without HIV (n=37 930)
Non-ART medication count 1·08 (1·07–1·08) 1·07 (1·07–1·08) 1·07 (1·06–1·07) 1·04 (1·03–1·05)
Age per 10 years  ·· 1·00 (0·99–1·02) 0·83 (0·81–0·84) 0·82 (0·81–0·84)
Sex
Female  ·· 0·91 (0·83–0·99) 0·83 (0·76–0·91) 0·85 (0·77–0·92)
Male 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Race
White, non-Hispanic 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Black, non-Hispanic  ·· 1·29 (1·25–1·33) 1·24 (1·20–1·28) 1·26 (1·22–1·29)
Hispanic  ·· 1·07 (1·02–1·13) 1·11 (1·05–1·16) 1·12 (1·06–1·17)
Other  ·· 0·57 (0·52–0·63) 0·59 (0·54–0·65) 0·60 (0·54–0·66)
VACS Index 2.0 per 5 points  ··  ·· 1·15 (1·15–1·16) 1·15 (1·14–1·16)
KPDI Index score
No KPDI  ··  ·· ·· 0·88 (0·84–0·93)
KPDI Index quintile 1  ··  ··  ·· 0·96 (0·91–1·01)
KPDI Index quintile 2  ··  ··  ·· 1 (ref)
KPDI Index quintile 3  ··  ··  ·· 1·10 (1·05–1·15)
KPDI Index quintile 4  ··  ··  ·· 1·22 (1·15–1·28)
KPDI Index quintile 5  ·· ··  ·· 1·34 (1·25–1·43)
Data are hazard ratios with 95% CIs in parentheses. ART=antiretroviral therapy. KPDI=known pairwise drug interaction. VACS= Veterans Aging Cohort Study. 
Table 3: Nested survival models of medication count and risk of hospitalisation
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every two medications added. However, when we linked 
DrugBank data with real-world data we observed five-to-
six times this number of interactions. Medications vary 
substantially in the number of other drugs with which 
they are known to interact. Our comparison of a random 
selection of drugs with real-world data underscores the 
nature of therapeutic medication selection; multiple 
medications are selected to treat specific conditions 
targeting specific mechanisms. Because medication 
targets can overlap, they are more likely to interact than if 
the medications were selected by chance.
By creating a KPDI Index weighted according to the 
average association of each pair with mortality, we 
accounted for this variation and optimised the ability of 
the KPDI Index to explain the association between non-
ART medication count and adverse outcomes. When we 
summed pairwise inter actions and their unadjusted 
component associations with survival into a severity 
index, we observed J-shaped associations with overall 
non-ART medication count and mortality rates. Although 
both people ageing with and without HIV infection in the 
lowest KPDI Index quintile were on more non-ART 
medications than those with no KPDI, they had lower 
mortality.
These associations suggest a benefit for a small 
number of medications, but this benefit was lost as the 
number of medications and total number of KPDIs 
increased among both people ageing with and without 
HIV. When an individual was on a large number of 
medications, the harmful effects of polypharmacy 
appeared to outweigh benefit. Previous work has often 
identified a threshold of five medications for adverse 
effects of polypharmacy.1 Our analyses suggest that 
medication counts as low as four might be problematic if 
associated with a high KPDI Index. However, if the KPDI 
Index is low, four or five medications might still be 
beneficial. Medication counts exceeding this threshold 
were associated with higher KPDI Index scores and 
crude mortality rates.
People ageing with HIV were on a lower number of 
non-HIV medications than those without ART, and their 
physiological frailty (as reflected in their VACS Index 2.0 
scores) was higher. We suspect that HIV-care providers 
are already concerned about polypharmacy and drug–
drug interactions, and are less likely to prescribe non-ART 
medications than general care providers. This finding is 
in contrast with studies that focused on polypharmacy 
among people ageing with HIV in which non-HIV and 
HIV care are provided in clinics that do not share a single 
electronic medical record. In these settings, people ageing 
with HIV had more polypharmacy than uninfected 
individuals,18,27,28 possibly because providers were unaware 
of medications prescribed in outside clinics.
Since the KPDI Index was weighted on the basis of 
observed mortality in this dataset, we considered risk of 
hospitalisation as a separate outcome, censoring on 
death or end of follow-up, using nested Cox models. We 
found that the KPDI Index accounted for a proportion of 
the association between medication count and risk of 
hospitalisation.
Although polypharmacy and physiological frailty are 
associated with each other, our analyses suggest that 
confounding by indication does not explain very much of 
the association between medication count and risk of 
hospitalisation. VACS Index 2.0 is a widely validated, 
highly discriminating, physiological index that is 
predictive of hospitalisation and mortality among 
veterans with and without HIV.12,21 The updated version 
of the VACS Index we used in this analysis meets or 
exceeds the discrimination of previous indices validated 
among older individuals.29 Yet, full adjustment for the 
VACS Index, did not elucidate the association between 
polypharmacy and hospitalisation. After adjustments, 
polypharmacy remained independently associated with 
risk of hospitalisation in a dose–response manner.
After adjustment, the associations between medication 
count and risk of hospitalisation were strong for both 
people ageing with and without HIV, but was somewhat 
stronger for people ageing with HIV. This finding 
suggests that people ageing with HIV might have greater 
susceptibility to harm from polypharmacy due to higher 
order drug interactions, increased toxicity, or greater 
physiological frailty. Consistent with this finding is the 
observation that 5613 (61%) of 9186 people ageing with 
HIV in this analysis were on a boosted protease inhibitor 
regimen, which has been associated with increased rates 
of drug–drug interactions.10,15 Although the use of boosted 
regimens has decreased since 2009, a study in Madrid, 
Spain, that ran from Jan 31 to June 30, 2017, found that 
23% of people ageing with HIV on antiretroviral 
medication were on a boosted regimen.18 Another 
possible reason for this increased susceptibility to harm 
due to polypharmacy is mitochondrial toxicity. All 
antiretrovirals included in ART have been shown to have 
some level of mitochondrial toxicity, as do many non-
ART medications.30–33 Concern about mitochondrial 
toxicity is increasing in the ageing population generally, 
not just among HIV-positive populations.30,34 Finally, the 
average additional 10 years of polypharmacy for people 
ageing with HIV might cause low level, chronic toxic 
side-effects to become symptomatic.
Only a randomised trial can definitively resolve issues 
of confounding, but designing effective interventions 
without an understanding of underlying mechanisms is 
difficult. Our analyses offer stronger real-world evidence 
than previously reported that polypharmacy causes 
excess hospitalisation, partially through KPDIs. It also 
suggests that KPDIs are not the only reason for this 
excess risk.
Future work is needed to determine how best to 
proceed. Expert criteria such as START/STOPP35 or 
Beers36 were developed for individuals without HIV who 
are older than 65 years, and evidence for the effectiveness 
of these criteria in avoiding actual adverse health 
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outcomes is contradictory and sparce. Although many 
studies in HIV-negative populations cite five medications 
as a critical threshold, no study has established a definitive 
threshold. Thresholds for injury probably depend on the 
specific regimen and associated drug interactions, the 
period of exposure, ongoing substance use, and the 
individual’s underlying physiological injury and genetic 
susceptibility.
ART regimens have evolved towards increased use of 
integrase strand transfer inhibitors and two-drug 
regimens, which will probably decrease the number of 
drug interactions and total medication count, so long as 
other non-ART medications are not added. People 
ageing with HIV on lifelong ART might continue to use 
alcohol and other substances that could interact with 
their medications and require special consideration. 
Sophisticated models will be needed, incorporating 
knowledge such as that contained in DrugBank, to 
account for what is known about drug–drug, 
drug–substance use, and pharmacogenetic interactions 
to aid the prescription of appropriate medications for 
these populations. Eventually, we will need to incorporate 
validated models into the clinical setting to help inform 
management of this complex problem.37
Our study has several strengths. The VACS has 
previously shown that the veterans without HIV in our 
sample are demographically, sociologically, and 
behaviourally similar to veterans living with HIV,38 
thereby limiting the possibility that observed differences 
are due to these factors. We had direct access to pharmacy 
dispensing data in a national system with generous 
pharmaceutical coverage. Because patients might not fill 
all their prescriptions, data on medication orders 
(prescriptions) are less informative than dispensing data. 
We considered the association between polypharmacy 
and hospitalisation rather than potential drug inter-
actions or other possible adverse effects. We compared 
health outcomes associated with polypharmacy among 
people ageing with HIV with demographically similar 
uninfected individuals. Our hospitalisation data are 
measured in a completely parallel manner among people 
ageing with and without HIV and include events 
occurring within the VA and care supported by other US 
Governmental sources (eg, Medicare and Medicaid).
Our study also has several limitations. The ART 
regimens that patients were undergoing reflect those in 
use in 2009. Use of this baseline was necessary for us to 
have adequate follow-up time for mortality endpoints that 
were used to weight the KPDI Index. Now that the 
methods and weighting have been developed, we plan to 
consider KPDIs among people ageing with and without 
HIV in more recent years. However, several studies from 
more recent periods suggest that people ageing with HIV 
continue to have more drug interactions than uninfected 
individuals.18,27 Our measures of medication count were 
conservative because they were based on medications 
dispensed within the VA and do not reflect outside 
prescriptions, over the counter, or complementary 
medications. Although people ageing with HIV in our 
sample were demographically similar to uninfected 
individuals, the strict 1:2 matching used in the VACS 
cohort was not preserved after the exclusions required for 
these analyses. The DrugBank database only reports 
KPDIs; it does not provide information concerning 
higher order (ie, greater than pairwise) interactions. We 
accounted for the severity of drug interaction by 
considering their average association with mortality and 
created a KPDI Index rather than using pre-existing 
weights included in DrugBank or other databases. In 
future, we hope to compare the explanatory power of our 
index against ones using pre-existing weights. 
Additionally, the nature of drug interactions is highly 
variable. We were not able to consider interactions with 
alcohol or other substances.39 We were not able to use any 
one of the many available approaches (including STOPP/
START35 or Beers36) to determining potentially 
inappropriate medications. Furthermore, an in-depth 
consideration of each specific drug regimen was beyond 
the scope of this study. This is an observational analysis of 
real-world data and is subject to unadjusted confounding. 
Finally, our analysis should be replicated in health-care 
systems including a larger proportion of women to enable 
generation of more generalisable findings.
Accounting for demographics and physiological frailty, 
both people ageing with and without HIV have increasing 
risk of hospitalisation when exposed to increasing counts 
of non-ART medication. This risk is partially explained 
by KPDIs. The number of KPDIs increase dramatically 
with increasing medication counts, well beyond what 
would be expected by chance, especially for people ageing 
with HIV. Nonetheless, a substantial proportion of the 
risk associated with medication count is not explained by 
demographics, physiological frailty, or KPDI, especially 
for people ageing with HIV. Unknown drug interactions, 
including higher order interactions, substance–drug 
interactions, and increased susceptibility to cumulative 
toxicity might each have a role. Sophisticated informatics 
tools are needed to better guide drug selection and 
deprescribing to avoid excess hospitalisations and 
mortality due to polypharmacy.
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